Holen Sie sich die Stockscreener-App
12.22
3.82%
0.45
Helus Pharma Inc Aktie (HELP) Neueste Nachrichten
Helus Pharma advances psychedelic treatments fo... - Pluang
Helus Pharma: An Undervalued Psychedelic Platform Approaching A Major Catalyst - Seeking Alpha
Cybin Stock Advances 5.23% as Phase 3 Depression Program, Leadership Expansion and Late-Stage Catalysts Lift Optimism - kalkine.ca
symbol__ Stock Quote Price and Forecast - CNN
HELP Stock Jumps 6% After TD Cowen Hikes Target Nearly 8x To $62 - Yahoo Finance
HELP Maintained by TD Cowen -- Price Target Raised to $62 - GuruFocus
TD Cowen raises Helus Pharma stock price target to $62 on trial timing - Investing.com Canada
Cybin (NYSE: HELP) plans 1.18M RSUs with first sale in 2026 - Stock Titan
Cybin Inc. (HELP) sets performance share plan through 2029 - Stock Titan
Helus Pharma stock rating reiterated at Buy by H.C. Wainwright - Investing.com Canada
Cybin (HELP) execs granted $12.6M shares as holders face 82% loss - Stock Titan
Helus Pharma Strengthens Leadership with Key Appointments as Pipeline Advances - citybuzz -
Cybin (HELP) adds exhibit to its base shelf registration - Stock Titan
How Helus’ new CEO plans to scale its psychedelic drug pipeline - Pharma Voice
Helus Pharma appoints former Intra-Cellular executives By Investing.com - Investing.com Canada
Helus Pharma Appoints Regina Donohue as Chief People Officer and Suresh Durgam, M.D., to its Scientific Advisory BoardTue, 08/18/202607:30 - Helus Pharma
Helus Pharma Inc (HELP) Q1 2026 Results Highlight Unprofitable S - GuruFocus
Helus Pharma Q1 Results: Net loss widens to $47.8M, cash at $166.4M - scanx.trade
Sirenia Capital (HELP) reports 3.03M-share Cybin stake including warrant shares - Stock Titan
Cybin : MDA Q1 27 FINAL - marketscreener.com
Cybin : Financial Statements Q1 27 FINAL - marketscreener.com
Helus Pharma (HELP) pushes Phase 3 depression and anxiety drug programs while managing cash needs - Stock Titan
Helus Pharma Appoints Michael Halstead CEO, Completes Enrollment in Phase 3 APPROACH Study of HLP003 and Reports Q2 2026 Results - Quiver Quantitative
Canada's Helus Pharma Q1 loss widens as R&D spending rises - TradingView
Helus Pharma Reports First Quarter Fiscal 2027 Financial Results and Recent Business HighlightsFri, 08/14/202607:28 - ir.helus.com
Helus Pharma finishes Phase 3 depression trial enrollment - Stock Titan
Cybin Conference: Helus CEO Eyes Q4 Phase III Depression Data for HLP003 - MarketBeat
Helus Pharma (CN: HELP) Names New CEO as Pivotal Depression Trial Nears Its Finish Line - kalkine.ca
HELP Stock Price and Chart — NEO:HELP - TradingView
Cybin Stock Builds Bullish Momentum as Clinical Catalysts Strengthen the HELP Outlook - kalkine.ca
Helus Pharma at Canaccord Genuity growth conference: phase iii test looms - Investing.com Nigeria
Adage Capital reports 5.29% Cybin Inc. (HELP) ownership, 3.29M shares - stocktitan.net
Cybin D/B/A Helus Pharma (HELP.NE) stock price, news, quote and history - Yahoo Finance UK
Cybin D/B/A Helus Pharma (HELP) Stock Price, News, Quote & History - Yahoo! Finance Canada
FDA Fast-Tracks Psychedelic Research After Trump’s Executive Order — CMPS, HELP Stocks Gain - Stocktwits
Helus Pharma (HELP) CEO to Join Canaccord Genuity Growth Conference Fireside Chat - Stock Titan
Cybin’s Helus Pharma to join Canaccord Genuity Annual Growth Conference fireside chat - Bitget
Helus Pharma to Participate at the Canaccord Genuity 46th Annual Growth Conference in Boston - investingnews.com
Cybin (HELP) Names New CEO, Is The Stock Still Cheap? - Yahoo! Finance Canada
Cybin (HELP) Is Up 33.1% After Hiring Helus Veteran Michael Halstead As CEO – Has The Bull Case Changed? - Yahoo Finance
Cybin (Helus Pharma, HELP) Leaps 14% Ahead of Pivotal Depression Trial Data - kalkine.ca
Could Helus Pharma’s New CEO Reframe Cybin’s (HELP) Path From Clinical Trials To Commercial Scale? - simplywall.st
Helus Pharma Shares Rise After Appointing New CEO - Moomoo
A CEO With a Proven Track Record of Success in Growing and Scaling Biopharmaceutical Companies Just Appointed CEO at a Clinical-Stage Biotech, Months Before Its Pivotal Phase 3 Readout - The Manila Times
A CEO With a Proven Track Record of Success in Growing and Scaling Biopharmaceutical Companies ... - caledonianrecord.com
A CEO With a Proven Track Record of Success in Growing and - GlobeNewswire
Helus Pharma appoints Michael Halstead as chief executive - Investing.com
Helus Pharma Appoints Michael Halstead as Chief Executive Officer - The Manila Times
Helus Pharma appoints Michael Halstead as chief executive By Investing.com - Investing.com India
Helus Pharma Appoints Former Intra-Cellular Therapies President Michael Halstead as CEO Ahead of Key HLP003 Phase 3 Readout - Quiver Quantitative
HELP Initiated Coverage by Wells Fargo -- Rating Set to Overweig - GuruFocus
HELP Initiated Coverage by Wells Fargo -- Rating Set to Overweight - GuruFocus
Helus Pharma Price Target Announced at $16.00/Share by Wells Fargo - Moomoo
Cybin (CYBN) Stock Fair Value Moves Lower As Analysts Rework Psychedelic Sector Assumptions - Yahoo Finance
0.86%
0.31%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):